FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly
The FDA has accepted a supplemental application for Emgality, CGRP inhibitor developed by Eli Lilly.
Asset / Drug
Drug and asset intelligence for Emgality with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
CGRP Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.